Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

PubWeight™: 2.14‹?› | Rank: Top 2%

🔗 View Article (PMC 3042860)

Published in Am Heart J on October 01, 2007

Authors

Ronald V Lacro1, Harry C Dietz, Lisa M Wruck, Timothy J Bradley, Steven D Colan, Richard B Devereux, Gloria L Klein, Jennifer S Li, L LuAnn Minich, Stephen M Paridon, Gail D Pearson, Beth F Printz, Reed E Pyeritz, Elizabeth Radojewski, Mary J Roman, J Philip Saul, Mario P Stylianou, Lynn Mahony, Pediatric Heart Network Investigators

Author Affiliations

1: Children's Hospital Boston and Harvard Medical School, Boston, MA 02115, USA. ron.lacro@cardio.chboston.org

Associated clinical trials:

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | NCT00429364

Articles citing this

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31

Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11

Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93

The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med (2011) 3.80

Lessons on the pathogenesis of aneurysm from heritable conditions. Nature (2011) 2.97

Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) (2010) 1.78

Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res (2011) 1.78

Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol (2009) 1.65

TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest (2010) 1.65

High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol (2013) 1.35

TGFβ signaling and cardiovascular diseases. Int J Biol Sci (2012) 1.35

Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett (2012) 1.31

The role of the renin-angiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep (2008) 1.28

Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation (2008) 1.18

Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J (2013) 1.14

Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest (2014) 1.13

Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res (2011) 1.10

Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr (2013) 1.09

The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure. J Ocul Pharmacol Ther (2014) 1.03

A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials (2013) 1.02

Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation (2014) 1.00

Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genet Med (2008) 0.98

Comparative measurement of aortic root by transthoracic echocardiography in normal Korean population based on two different guidelines. Cardiovasc Ultrasound (2013) 0.95

Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials. Am J Med Genet C Semin Med Genet (2009) 0.95

A healthy tension in translational research. J Clin Invest (2014) 0.95

Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J (2011) 0.94

Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice. Arterioscler Thromb Vasc Biol (2015) 0.93

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. Am Heart J (2015) 0.88

The pathology and pathobiology of bicuspid aortic valve: State of the art and novel research perspectives. J Pathol Clin Res (2015) 0.87

Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy. Eur J Pediatr (2012) 0.82

Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. Br J Pharmacol (2009) 0.82

Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions. Curr Cardiol Rev (2014) 0.81

Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One (2013) 0.81

Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics. BMC Musculoskelet Disord (2010) 0.81

Impact of Mendelian inheritance in cardiovascular disease. Ann N Y Acad Sci (2010) 0.80

The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet J Rare Dis (2014) 0.79

Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients. Mt Sinai J Med (2010) 0.78

Bicuspid aortic valve and thoracic aortic aneurysm: three patient populations, two disease phenotypes, and one shared genotype. Cardiol Res Pract (2012) 0.78

Fibrillin-containing microfibrils are key signal relay stations for cell function. J Cell Commun Signal (2015) 0.78

The pathogenesis of aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep (2010) 0.77

Hereditary Influence in Thoracic Aortic Aneurysm and Dissection. Circulation (2016) 0.77

Genes in thoracic aortic aneurysms/dissections - do they matter? Ann Cardiothorac Surg (2013) 0.76

Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol (2010) 0.76

BMP signaling modulation attenuates cerebral arteriovenous malformation formation in a vertebrate model. J Cereb Blood Flow Metab (2014) 0.76

Genes in Thoracic Aortic Aneurysms and Dissections - Do they Matter?: Translation and Integration of Research and Modern Genetic Techniques into Daily Clinical Practice. Aorta (Stamford) (2013) 0.75

Genetics for the general internist. Am J Med (2011) 0.75

Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. Br J Clin Pharmacol (2011) 0.75

AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation? Arterioscler Thromb Vasc Biol (2014) 0.75

Novel pharmacological strategies to prevent aortic complications in Marfan syndrome. J Geriatr Cardiol (2011) 0.75

Association between Oro-Facial Defects and Systemic Alterations in Children Affected by Marfan Syndrome. J Clin Diagn Res (2013) 0.75

The pediatric heart network: meeting the challenges to multicenter studies in pediatric heart disease. Curr Opin Pediatr (2015) 0.75

Genetic diagnostics of inherited aortic diseases : Medical strategy analysis. Herz (2017) 0.75

Articles cited by this

A multiple testing procedure for clinical trials. Biometrics (1979) 26.80

Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature (1991) 11.44

Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet (2003) 11.01

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62

Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet (1996) 7.84

Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med (1994) 5.03

Marfan's syndrome. Lancet (2005) 4.99

TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest (2004) 4.85

Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med (1999) 4.17

Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem (2002) 3.92

Life expectancy in the Marfan syndrome. Am J Cardiol (1995) 3.14

Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg (2002) 3.03

Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int (1997) 2.82

Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem (1991) 2.47

Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J (2004) 2.44

Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg (2006) 2.25

The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol (2006) 1.86

Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol (2005) 1.81

Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation (2001) 1.63

Marfan Database (third edition): new mutations and new routines for the software. Nucleic Acids Res (1998) 1.49

Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res (2000) 1.42

Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol (1999) 1.35

Growth and maturation in Marfan syndrome. Am J Med Genet (2002) 1.28

Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol (1994) 1.24

Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development. Matrix Biol (2003) 1.20

Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation (1995) 1.13

Management of Marfan syndrome. Heart (2002) 1.11

Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. Semin Thorac Cardiovasc Surg (1993) 1.10

Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr (2007) 1.05

Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr (1999) 1.05

Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther (1977) 1.01

Articles by these authors

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39

Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet (2003) 11.01

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62

Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med (2006) 9.50

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31

The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 6.87

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med (2007) 6.22

Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15

Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet (2004) 6.14

Exosome-mediated recognition and degradation of mRNAs lacking a termination codon. Science (2002) 5.46

Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med (2010) 5.43

Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol (1985) (2004) 5.29

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25

An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science (2002) 5.22

Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11

Marfan's syndrome. Lancet (2005) 4.99

TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest (2004) 4.85

Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA (2006) 4.51

Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49

Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA (2007) 4.27

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20

Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr (2010) 3.96

Separable roles for rent1/hUpf1 in altered splicing and decay of nonsense transcripts. Science (2002) 3.84

Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med (2010) 3.81

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78

Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 3.70

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68

Aneurysms of the sinuses of Valsalva. Cardiology (2006) 3.64

Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr (2004) 3.55

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (2011) 3.49

Treatment of aortic disease in patients with Marfan syndrome. Circulation (2005) 3.48

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42

The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med (2003) 3.28

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science (2011) 3.18

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16

Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation (2010) 3.13

Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04

Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest (2004) 3.01

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab (2010) 2.99

Lessons on the pathogenesis of aneurysm from heritable conditions. Nature (2011) 2.97

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96

Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet (2006) 2.94

Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension (2007) 2.94

Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA (2006) 2.92

Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol (2008) 2.91

Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90

Dissection of epistasis in oligogenic Bardet-Biedl syndrome. Nature (2005) 2.90

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 2.85

Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet (2002) 2.85

Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet (2013) 2.82

Insects breathe discontinuously to avoid oxygen toxicity. Nature (2005) 2.79

Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation (2007) 2.76

Strategies for implementing screening for critical congenital heart disease. Pediatrics (2011) 2.72

Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69

Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol (2004) 2.68

Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med (2005) 2.68